Janusita Plus Tablet 50/500 mg
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jeil Pharmaceutical Co., Ltd.
MFDS item code 201503220 · Approved 2015.05.27
This product's status changed to Expired on 2025.05.27. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is prescribed to assist in blood sugar control for patients with type 2 diabetes when sitagliptin and metformin are used together. It effectively manages blood sugar levels when used alongside dietary and exercise therapies, helping to improve blood sugar control for patients.
For antidiabetic therapy, determine the dose of this medicine based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients in whom administration is contraindicated). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's current metformin dose. - Patients switching to this medicine from combination therapy with sitagliptin and metformin may start with their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take into account the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have evaluated the safety and efficacy of switching patients previously treated with another oral blood glucose-lowering agent to this medicine. Any change in treatment for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in whom administration is contraindicated).
This medication contains sitagliptin and metformin and is used for the treatment of diabetes. First, during the use of this medication, serious allergic reactions may occur, so if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck appear, discontinue use immediately and consult a doctor. Also, this medication may cause pancreatitis, so symptoms like abdominal pain, vomiting, or nausea should be promptly reported to medical staff. The metformin component can lead to a rare but serious metabolic disorder called lactic acidosis, so if sudden muscle pain, difficulty breathing, severe fatigue, or abdominal pain occurs, stop treatment immediately and visit a hospital. This medication should not be used in patients with poor kidney function or those with severe infections, dehydration, heart failure, or liver disease. In particular, the use of this medication should be temporarily discontinued before and after tests using radiologic contrast agents, and should be restarted only after confirming normal kidney function. Pregnant or potentially pregnant women and nursing mothers should not take this medication. Regular blood tests and kidney function tests should be performed during treatment, and periodic checks of vitamin B12 levels are advisable. Additionally, as there is a risk of hypoglycemia, caution should be exercised when skipping meals or engaging in vigorous exercise, and the risk of hypoglycemic symptoms can increase when taken with other hypoglycemic agents or alcohol. If surgery is planned, this medication should be discontinued 48 hours prior to the surgery and restarted only after confirming the return of normal kidney function after the operation. Finally, it is advisable to avoid alcohol consumption during the course of taking this medication.
Severe hypersensitivity reactions, anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory tract infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, constipation, arthralgia accompanied by severe and disability, blistering dermatitis herpetiformis, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, dermatitis, anorexia, weight loss, dyspnea, unstable angina, dizziness, acute renal failure, decreased appetite, gastrointestinal disturbances, itching
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in an airtight container and kept at a temperature between 1 and 30 degrees Celsius. Proper storage will maintain the effectiveness of the medication and ensure its safe use.
Bright pink oval film-coated tablet
30 tablets (10 tablets/PTP*3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jeil Pharmaceutical Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkun Dang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
Jong Kun Dang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
JongKeunDang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.